Ryniant Sciences
Ryniant Sciences is a nonprofit biotech organization based in Phoenix, Arizona, focused on transforming drug discovery and healthcare through AI-driven innovation. Their flagship product, the Ominor Platform, integrates machine learning, multi-omics, and clinical data to accelerate development of targeted therapies for rare, neglected, and complex diseases. The company operates a decentralized subsidiary model with specialized divisions such as NeuroLuma, RarusLuma, and CutisLuma, each focusing on neurological, rare disease, and dermatological treatments respectively, leveraging the Ominor AI core. Ryniant also develops public health and health informatics tools like Bluvia and Calrivis Alpha Z1. Their business model emphasizes open access, collaboration with academic and industry partners, and modular growth to optimize resources and scale innovations globally. The organization is student-led with expert advisory backing and aims to democratize biotech innovation and improve global health outcomes.
Ryniant Sciences
Ryniant Sciences is a nonprofit biotech organization based in Phoenix, Arizona, focused on transforming drug discovery and healthcare through AI-driven innovation. Their flagship product, the Ominor Platform, integrates machine learning, multi-omics, and clinical data to accelerate development of targeted therapies for rare, neglected, and complex diseases. The company operates a decentralized subsidiary model with specialized divisions such as NeuroLuma, RarusLuma, and CutisLuma, each focusing on neurological, rare disease, and dermatological treatments respectively, leveraging the Ominor AI core. Ryniant also develops public health and health informatics tools like Bluvia and Calrivis Alpha Z1. Their business model emphasizes open access, collaboration with academic and industry partners, and modular growth to optimize resources and scale innovations globally. The organization is student-led with expert advisory backing and aims to democratize biotech innovation and improve global health outcomes.